Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPaweł RobakKKKihyun KımEGEsther González García

Discussion

Loading...

Member takes

Overview

Randomized trials demonstrated belantamab mafodotin's benefit on progression-free survival in patients with high-risk multiple myeloma, highlighting its favorable safety profile.

Key Points

  • To evaluate the efficacy and safety of belantamab mafodotin in relapsed/refractory multiple myeloma patients with functional high-risk characteristics.
  • Patients with relapsed/refractory multiple myeloma were randomized to receive either belantamab mafodotin combinations or control regimens.
  • Primary endpoint was progression-free survival assessed by an independent review committee.
  • Descriptive statistics analyzed response rates, minimum residual disease negativity, and adverse events.
  • Belantamab mafodotin showed a significant improvement in progression-free survival compared to conventional treatments.
  • Higher rates of minimum residual disease negativity were observed in patients treated with belantamab mafodotin.
  • Adverse events were documented, with a notable proportion of grade 3/4 treatment-related adverse events in both arms.

Cite This Study

Robak et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d185https://doi.org/10.1182/blood-2025-5820
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change2025
  2. 2Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial2025 · 1 citations
  3. 3Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study2025 · 4 citations
  4. 4Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis2025
  5. 5Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy2025